Red Biotechnology Market, By Application (Biopharmaceutical Manufacture, Pharmacogenomics, Gene Therapy, and Genetic Testing), By End-user (Biopharmaceutical Business, Research Organizations, CMOs & CROs, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2029

Report Code: PMI435320 | Publish Date: March 2024 | No. of Pages: 170

Global Red Biotechnology Market Overview

Red biotechnology is one of the fields of biotechnology. Biotechnology is spreading its roots everywhere, with the advancement in the world. Red biotechnology is a field that deals with human healthcare, health preservation, and pharmaceutical. The scientists exploit living systems to develop and produce antibiotics, vaccines, therapies, and new diagnostic methods. It is the field that deals with drug discovery, pharmacogenomics, personalized medicine, gene therapy, and genetic testing. Further, red biotechnology also has its application in cancer research and biochip production. The red biotechnology market accounted for US$ 353.1 billion in 2019 and is estimated to be US$ 584.8 billion by 2029 and is anticipated to register a CAGR of 5.2%.

Impact of Covid-19 pandemic on market

Due to the outbreak of COVID-19, biopharmaceutical innovators are at the forefront of the human response. A huge number of foremost biotech companies are in the midst of a race to explore the Sars-Cov-2 genome and prepare a viable vaccine for the same. With multiple aspirants in the trial, the public and private sectors are expected to work in unison in the coming years, until a vaccine is developed for Covid-19. The report will estimate for Covid19 as a significant market contributor.

Global Red Biotechnology Market Dynamics

Increasing demand for therapeutics to drive new potentials

The increasing prevalence of chronic diseases is fascinating researchers to develop advanced drugs and therapeutics that are proficient in battling chronic and progressive diseases. Further, due to continuous developments in therapeutics for an array of diseases, and perpetual efforts towards effective R&D for drug development, product approvals by international regulatory bodies are obtaining major traction, thus driving developments in the red biotechnology market.

Substantial investments in the healthcare sector

There is an incessantly rising buoyancy for supporting industries in the biotech sector, including health service firms. Healthcare start-ups are admiring intensely for investors, principally in areas such as biotechnology. The healthcare industry, as a whole, has cited that dollars of investments and higher valuations are likely to stay consistent throughout the forecast period, giving an edge to research activities for biopharmaceutical production.

However, the high cost of manufacturing and the high failure rate of late-stage drug products in clinical trials are major factors hampering the red biotechnology market growth. Significantly large funds are needed for the research and development of therapeutics, which results in the higher prices of therapeutics and leads to concerns regarding funds, thus, limiting the penetration of therapeutics in emerging economies that provides significant opportunities.

Global Red Biotechnology Market Segmentation

The red biotechnology market is segmented based on application, end-user, and region.

On the basis of the application, the red biotechnology market is segmented into biopharmaceutical manufacture, pharmacogenomics, gene therapy, and genetic testing. Based on the end-user, the target market is segmented into biopharmaceutical business, research organizations, CMOs & CROs, and others.

In the region, the red biotechnology market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America estimates for the highest share of the red biotechnology market in 2018. The region is projected to continue its dominance in the red biotechnology market in the coming years. A higher rate of adoption of new diagnostics and therapeutics along with the growing demand for efficient drug products is expected to fuel the red biotechnology market in North America. In Europe, the market is projected to grow at a substantial growth rate in the near future, due to rising product approvals, increasing prevalence of genetic disorders, rising mergers & acquisitions, and surging funding for research & development. Further, in the Asia Pacific, the target market is likely to grow at a substantial CAGR in the coming years. Increasing mergers & acquisitions and product approvals in the region from respective regional authorities are expected to dive into the red biotechnology market over the forecast period. For instance, in May 2019, Takeda Pharmaceutical Company declared the agreement of Entyvio by the Ministry of Health, Labour, and Welfare in Japan for the treatment of adult patients with moderately to severely active Crohn’s disease.

Attribute

Details

The base year for estimation

2019

Forecast period

2019 – 2029

Market representation

Revenue in USD Million & CAGR from 2019 – 2029

Market Segmentation

By Application– Biopharmaceutical Manufacture, Pharmacogenomics, Gene Therapy, and Genetic Testing

By End-user– Biopharmaceutical Business, Research Organizations, CMOs & CROs, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029.  For the purpose of this study, has segmented the red biotechnology market report based on application, end-user, and region.

 Red Biotechnology Market, By Application:

  • Drug Development
  • Molecular Genomics
  • Gene Therapy
  • Personalized Medicines
  • Others

Red Biotechnology Market, By End-user:

  • Biopharmaceutical Business
  • Research Organizations
  • CMOs & CROs
  • Others

Red Biotechnology Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
      • U.S.
      • Canada

Global Red Biotechnology Market Key Players

The key players operating in the red biotechnology market include Biogen Inc., Pfizer, Inc., Amgen Inc., AstraZeneca Plc., CELGENE CORPORATION, Gilead Sciences, Inc., F. Hoffmann-La Roche, Ltd., Regeneron Pharmaceuticals, Inc., Merck KGaA, and Takeda Pharmaceutical Company Limited. Companies operating in the red biotechnology market are expanding their focus towards the expansion of geographic presence through partnerships, strategic mergers & acquisitions, and product launches in different regions and countries, thus merging their position in the red biotechnology market.

Global Red Biotechnology Market Company Profile

  • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc.
  • CELGENE CORPORATION
  • Glead Sciences, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited

 “*” marked represents similar segmentation in other categories in the respective section

Global Red Biotechnology Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Red Biotechnology Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Application
      • Market Snippet, By End-user
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Red Biotechnology Market, By Application, 2019 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
      • Y-o-Y Growth Analysis (%), 2019 – 2029
      • Segment Trends
    • Biopharmaceutical Manufacture
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Pharmacogenomics
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Gene Therapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Genetic Testing
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
  6. Global Red Biotechnology Market, By End-user, 2019 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
      • Y-o-Y Growth Analysis (%), 2019 – 2029
      • Segment Trends
    • Biopharmaceutical Business
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Research Organizations
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • CMOs & CROs
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Other End-user
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
  7. Global Red Biotechnology Market, By Region, 2019 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
      • Y-o-Y Growth Analysis (%), 2019 – 2029
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Application, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Application, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Application, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Application, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
      • Market Size  and Forecast (US$ Mn), By Country, 2019 – 2029
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Application, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  9. Company Profiles
      • Biogen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Business Strategies
      • Pfizer, Inc.
      • Amgen, Inc.
      • AstraZeneca Plc.
      • CELGENE CORPORATION
      • Glead Sciences, Inc.
      • F. Hoffmann-La Roche, Ltd.
      • Regeneron Pharmaceuticals, Inc.
      • Merck KGaA
      • Takeda Pharmaceutical Company Limited
  10. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Global Red Biotechnology Market is segmented into application, end-user, and region.

Due to continuous developments in therapeutics for an array of diseases, and perpetual efforts towards effective R&D for drug development, product approvals by international regulatory bodies are obtaining major traction, thus driving developments in the red biotechnology market.

By region, North America estimates for the highest share of the global red biotechnology market in 2018. The region is projected to continue its dominance in the global red biotechnology market in the coming years.

The Key players operating in the Global Red Biotechnology Market include Biogen Inc., Pfizer, Inc., Amgen Inc., AstraZeneca Plc., CELGENE CORPORATION, Gilead Sciences, Inc., F. Hoffmann-La Roche, Ltd., Regeneron Pharmaceuticals, Inc., Merck KGaA, and Takeda Pharmaceutical Company Limited.